How does SaiyanMed select trustworthy raw materials carefully?
When you’re working with research-grade peptides, the starting point isn’t the synthesis or the lyophilization—it’s the raw material. If the raw material is inconsistent or impure, nothing downstream can fix it. That’s why SaiyanMed puts an obsessive focus on how they source and verify every single gram of peptide raw material. The short answer is: they don’t rely on a single supplier, and they don’t take certificates at face value. Instead, they combine a materials science background, direct manufacturer partnerships, and independent third-party verification to ensure that what arrives at their US warehouse is exactly what the label says.
Let’s break down the specifics. The founder, Eric, holds a Bachelor’s degree in Materials Science from one of China’s leading universities, specializing in biomaterials. That’s not just a line on a resume—it directly shapes how the company evaluates raw material quality. Instead of buying from the cheapest bulk chemical trader, SaiyanMed sources raw materials from manufacturers that meet specific criteria: documented GMP compliance, consistent batch-to-batch purity above 98%, and transparent supply chain records. For example, for a peptide like BPC-157, they require the manufacturer to provide a full synthesis report, including the exact reagents used, the purification method (typically HPLC), and the final purity percentage. If any of that is missing, the material doesn’t move forward.
But they don’t stop at paperwork. Every incoming raw material batch undergoes a preliminary in-house screening using HPLC (High-Performance Liquid Chromatography) to check for gross impurities. This is a rapid pass/fail step—if the material doesn’t hit a minimum purity threshold of 97%, it gets rejected immediately. That alone filters out a significant portion of low-quality material. According to internal data shared in their operational reports, approximately 12% of raw material batches from new suppliers fail this initial screening, and those suppliers are either dropped or required to re-test and re-submit.
The real differentiator comes after that preliminary pass. SaiyanMed sends every single batch to an independent, third-party lab—Janoshik Analytical—for full verification. Janoshik is widely recognized in the peptide research community for its rigorous testing protocols, including mass spectrometry (MS) for molecular weight confirmation, HPLC for purity quantification, and sometimes NMR (Nuclear Magnetic Resonance) for structural confirmation. The results are published as openly verifiable Certificates of Analysis (CoAs) that researchers can check directly. This isn’t a spot-check or a once-a-month audit; it’s per batch, per peptide. For a typical order of 10 vials of a peptide like Tirzepatide or Semaglutide, the batch number on the vial corresponds directly to a Janoshik report that you can pull up online. That level of transparency is rare in the industry, where many suppliers either skip third-party testing or only test a single batch and then claim it applies to all subsequent batches.
Here’s a concrete example of how this plays out with data. In a recent batch of a common research peptide (let’s call it “Peptide X” for confidentiality), the manufacturer’s certificate claimed 99.2% purity. Janoshik’s independent test came back at 98.7% purity—still high, but not matching the claim. SaiyanMed flagged the discrepancy, quarantined the entire batch, and went back to the manufacturer to investigate. The issue turned out to be a slight degradation during shipping due to temperature fluctuation. That batch was never released to customers. Instead, it was either returned to the manufacturer or destroyed, depending on the contract terms. This kind of real-world deviation happens more often than most researchers realize, and the only way to catch it is to test every batch independently.
Let’s look at a comparison table that shows how SaiyanMed’s raw material selection process stacks up against common industry practices:
| Selection Criteria | Typical Industry Practice | SaiyanMed Practice |
|---|---|---|
| Supplier Qualification | One-time vetting, often based on price | Continuous vetting with GMP documentation and synthesis reports per batch |
| Incoming Inspection | Visual check or no check | HPLC screening for purity >97% threshold |
| Third-Party Testing | Spot-check or no testing | Every batch tested by Janoshik (HPLC + MS + optional NMR) |
| Batch Rejection Rate | Unknown or low (due to lack of testing) | ~12% failure rate at initial screening, plus additional rejections after third-party tests |
| CoA Transparency | Internal CoA or no CoA | Openly verifiable Janoshik reports linked to batch numbers |
| Temperature Control | Often ignored during raw material transport | Temperature-logged shipping for sensitive peptides |
The table highlights a critical point: the rejection rate of 12% at the initial screening stage is not a sign of poor sourcing—it’s a sign of rigorous selection. Most companies in this space simply accept whatever the supplier sends, because testing costs money and time. SaiyanMed treats that cost as a non-negotiable part of the process. They’ve built their entire logistics and quality framework around this principle. Their US-based warehouse is not just for faster shipping; it also allows them to control storage conditions—temperature, humidity, and light exposure—which directly affect raw material stability. For example, peptides like Melanotan II and GHRP-6 are notoriously sensitive to heat, and storing them at improper temperatures can degrade purity by 5-10% within weeks. By keeping inventory in a climate-controlled US facility, they minimize that risk.
Another layer of detail: the company’s joint manufacturing partnerships. SaiyanMed doesn’t just buy raw materials off the shelf; they work directly with manufacturers to specify exact synthesis parameters. For instance, they might require a specific type of resin for solid-phase peptide synthesis, or a particular gradient for HPLC purification. This level of specification ensures that the raw material they receive is not just “pure” in a general sense, but consistent in its structural integrity. A peptide that’s 99% pure but has a slightly wrong stereochemistry is functionally different from the intended compound. That’s why they include mass spectrometry in their testing protocol—it confirms the molecular weight and, by extension, the correct amino acid sequence.
Let’s talk numbers again. According to publicly available Janoshik reports for SaiyanMed batches (which you can find on the Janoshik website or through links provided on the saiyanmed product pages), the average purity across all tested peptides in the last six months is 98.9%, with a standard deviation of 0.4%. That means the vast majority of batches are within a tight purity range. Compare that to industry averages, where many suppliers claim 99% but actual third-party tests often reveal 95-97% purity, with occasional batches dipping below 90%. The difference is not academic—impurities like truncated peptides, residual solvents, or endotoxins can confound research results, leading to false conclusions or wasted animal studies.
The company also maintains a strict policy on raw material traceability. Each batch is assigned a unique internal code that tracks it from the manufacturer’s facility through the initial screening, third-party testing, lyophilization (if applicable), and final packaging. This traceability is documented in their internal quality management system, which is audited quarterly. While they don’t publish the full traceability chain for proprietary reasons, they do provide batch numbers on every vial and link those to the Janoshik CoA. That’s more than most competitors offer.
One more practical detail: SaiyanMed does not rely on a single raw material supplier for any given peptide. They maintain a rotating list of qualified suppliers, typically 2-3 per compound, to avoid supply chain disruptions and to have a backup if one supplier’s quality dips. This is a direct result of Eric’s materials science background—he knows that even the best manufacturer can have a bad batch, and having a secondary source ensures continuity without compromising quality. The supplier qualification process is repeated annually, with each supplier required to submit new GMP documentation and a fresh batch for independent testing.
Finally, it’s worth noting that SaiyanMed openly states that all their compounds are strictly for laboratory research and in-vitro evaluation only, not for human consumption. This is not just a legal disclaimer—it’s a reflection of their quality philosophy. Because they’re not aiming for pharmaceutical-grade human use, they could theoretically cut corners. But they don’t. The same rigorous raw material selection process applies whether the peptide is for a university lab studying metabolic pathways or a private researcher investigating muscle regeneration. The standard is the same: verified, traceable, and independently tested. That’s how they select trustworthy raw materials carefully—not by trusting a single piece of paper, but by building a system that verifies every claim, every batch, every time.